Compare Paychex, Inc. (PAYX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs TransMedics Group Inc — how do they compare? Paychex, Inc. trades at $103.98 (market cap $37.19B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Paychex, Inc. is far larger — about 13.6× TransMedics Group Inc's market cap, and Paychex, Inc. pays a 4.56% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and TransMedics Group Inc for 24 Days on average.
| PAYX | TMDX | |
|---|---|---|
Market Cap | $37.19B | $2.74B |
Volume | 3,344,316 | 949,331 |
Sector | Industrials | Health |
52-Week High | $128.59 | $150.42 |
52-Week Low | $85.57 | $61.99 |
Typical Hold Time | 56 Days | 24 Days |
Enterprise Value | $40.87B | $3.13B |
Dividend Yield | 4.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $104.46, up 2.87% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company continues to deliver strong fundamentals, beating earnings estimates for the last three quarters with a net income margin of 27.35% and robust ROE of 47.06%. Recent news highlights earnings beats but also concerns over stock performance and dividend sustainability despite a recent 5-star rating from Newsweek.
The stock presents a cautious opportunity with a consensus price target of $111 offering ~6% upside, but risks include a high P/E of 20.73, significant debt increase, and sensitivity to labor market trends. Investor sentiment is divided, with analyst consensus leaning Hold, reflecting balanced growth prospects against valuation and macroeconomic headwinds.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
